Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680146 | 1.00 | TTR (0.58) | TTRAPPMAOBMAOAPTPN1 | |
| SCHEMBL28735753 | 0.88 | TTR (0.58) | TTRAPPMAOBMAOAPTPN1 | |
| SCHEMBL31560386 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL6960198 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL6960203 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL23927509 | 0.84 | TTR (0.61) | TTRAPPMAOBPTPN1CA12 | |
| SCHEMBL22273094 | 0.84 | TTR (0.61) | TTRAPPMAOBPTPN1CA12 | |
| SCHEMBL1907799 | 0.84 | TTR (0.61) | TTRAPPMAOBMAOACA12 | |
| SCHEMBL1932621 | 0.84 | TTR (0.61) | TTRAPPMAOBMAOACA12 | |
| SCHEMBL2847487 | 0.83 | TTR (0.59) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-03-02 | — | — | US | disclosed |
| EP-4073057-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2022-10-19 | — | — | EP | disclosed |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| WO-2021129817-A1 | PYRIMIDINE-BASED COMPOUND HAVING INHIBITORY EFFECT OF KETOHEXOKINASE (KHK) | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021116005-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115560-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115560-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
| EP-2134703-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-12-23 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| WO-2008110008-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| CN-101031539-A | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORP (JP) | 2007-09-05 | — | — | CN | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | TTR 2202/4885APP 2099/4885MAOB 1943/4885 |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | CACNA1G, KCNN4, CACNA1E | TTR 3102/4885APP 672/4885MAOB 582/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TTR 3315/4885APP 3879/4885MAOB 886/4885 |
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | FYN, SRC, PTK2B | TTR 1669/4885APP 1892/4885MAOB 957/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | TTR 769/4885APP 4012/4885MAOB 736/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | TTR 3315/4885APP 3879/4885MAOB 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.